Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great News article on $CBSC!
$CBSC on ALERT! CB Scientific, Inc. (Stock Symbol: CBSC) is a Rising Entry into the Multi-Billion Dollar Cardiac Monitoring Medical Device and Technology Software Field with FDA and CE Cleared Products & Technology https://www.marketwatch.com/press-release/cb-scientific-inc-stock-symbol-cbsc-is-a-rising-entry-into-the-multi-billion-dollar-cardiac-monitoring-medical-device-and-technology-software-field-with-fda-and-ce-cleared-products-technology-2021-02-22?reflink=mw_share_twitter
Nice $CBSC volume in the first 90 minutes...
Nice! Closing strong!
CBSC
$CBSC is green and trading 20k shares over their 10-day average volume!
$CBSC The Stock Day Podcast welcomed CB Scientific, Inc. (CBSC)(“the Company”), a company transitioning to the Ambulatory Remote Cardiac Monitoring market. CEO of the Company, Chip Martin, joined Stock Day host Everett Jolly.
https://audioboom.com/posts/7807543-cb-scientific-inc-discusses-the-potential-of-their-proprietary-cardiac-event-monitor-my-cam-w
This is some amazing technology developed by $CBSC!
“Our device is cardiac event monitoring, which is a device that can be worn for up to 30 days,” said Martin. “Instead of recording everything, this device records a snapshot around when a rhythm problem might occur,” he continued. Martin then explained that the snapshot can then be delivered to a physician via the Company’s iOS or Android applications to determine whether or not a cardiac problem occurred.
“The device also has a sophisticated algorithm in it that looks at fast, slow, irregular, and delayed heart rates,” said Martin. “That particular application has evolved into what’s called cardiac event monitoring, which is on the marketplace today, primarily in the US.”
$CBSC on ALERT with HUGE ACQUISITION NEWS as CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF) https://finance.yahoo.com/news/cb-scientific-inc-announces-definitive-123000184.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
She is setup for a big move. $CBSC
$CBSC - Martin shared that the Company began transitioning to the Ambulatory Remote Cardiac Monitoring market in June of last year. “This allows us to deal with the early detection of cardiac heart rhythms in hospitals and with cardiologists and physicians around the world and the efforts to diagnose ECG earlier and decrease the amount of deaths related to heart failure,” shared Martin. https://cbscientificinc.com/cb-scientific-inc-discusses-the-potential-of-their-proprietary-cardiac-event-monitor-my-cam-with-the-stock-day-podcast/?fbclid=IwAR26rh0227QKi0WlyxAvoau1r3q_VIVxwIcYggcVTiaQ-e7rAOILG_ujwTc
CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)
Addition of IDTF operation has CBSC well-positioned to significantly impact the US Remote Patient Monitoring market.
February 24 2021 - 10:05AM
InvestorsHub NewsWire
ESCONDIDO, CA -- February 24, 2021 -- InvestorsHub NewsWire -- CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring Services market in the United States, is pleased to announce a definitive purchase agreement to acquire Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) based in Levittown, New York. Cardiolink was founded in 1979 and has been providing remote heart arrhythmia monitoring and cardiac support services to the medical community regionally for forty-two years.
This acquisition will provide CBSC with the ability to formally enter the rapidly growing Remote Patient Monitoring (RPM) arena in the US, on a national basis. RPM has become a dominate growth market in the medical field since 2017, primarily due to the increasing occurrence of cardiovascular (heart) disease. Cardiolink, through their 24/7/365 operation, uses state-of-the-art cardiac equipment and software to deliver a wide variety of remote ambulatory cardiac testing services to patients. These wearable devices include Mobile Cardiac Telemetry, Cardiac Event, Extended Holter, Standard Holter and Ambulatory Blood Pressure, all monitored by an experienced staff of well-trained, expert cardiac technicians. Cardiolink also provides remote Pacemaker TTM monitoring and INR heart testing. This acquisition will make CBSC an active player in the domestic Ambulatory Remote Cardiac Diagnostic Monitoring Services market, which generated revenues of approximately US $778M in 2019, with projected future growth of 18% per year.
"Cardiolink is very excited to join the CB Scientific, Inc. team in their efforts to address the increasing demand for remote cardiac monitoring services in the U.S.", said Robert Kammerer, President of Cardiolink Corporation in a statement. Kammerer continued, "With forty-two years of direct experience offering IDTF products and services regionally, Cardiolink looks forward to being a part of CBSC's planned national expansion to further help impact and improve the quality of life and reduce the cost of care for the millions of patients with suspected heart disease, in the U.S."
Charles Martin, President and CEO of CB Scientific, Inc. stated, "The acquisition of Cardiolink Corporation fits perfectly into our strategic plan and efforts to positively impact outcomes for the more than 655,000 Americans who die from heart disease in the United States every year. Cardiovascular disease is the leading cause of death in the US, killing one in every four people every year, and costing the US more than $219B annually. The addition of this well-established, proven company, along with our existing and future products and services, will help to solidify CBSC's expanded service offering in our efforts to become a leader in the US Remote Patient Monitoring market. Timely and early detection of potential heart rhythm issues is the key to better diagnosis and improved outcomes, reducing cost and helping to improve quality of life for patients. We look forward to the positive effects that the addition Cardiolink's IDTF operation will have for our company."
As part of CBSC's 2021 business plan, this transaction will help to significantly increase productivity by addressing the ever-increasing demands for remote cardiac services, as well as increasing our revenues, thereby allowing for possible expansion into future alternative markets. Today, the US is at the forefront of Remote Cardiac Monitoring, with lower percentage death rates due to cardiovascular disease, than the rest of the world. Related to this acquisition will be on-going efforts by CBSC to expand My-Cardia's service capabilities globally, where deaths from heart disease in some countries run upwards to 40%. We hope to make a positive impact on these areas of the world by improving earlier diagnosis of heart disease through our products and services. Plans also include leveraging business relationships and exploring additional acquisitions. The Cardiolink acquisition is targeted to be completed by May 2021.
CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
About Cardiolink Corporation:
CardioLink Corp., founded in 1979, has been providing life-saving cardiac support services for physicians and patients, via transtelephonic monitoring equipment for 42 years. The company was incorporated in 1988 and moved from its original facility in Carle Place, NY to a larger facility in Levittown, NY as the company expanded. CardioLink Corp. provides Wireless Telemetry, Cardiac Event Arrhythmia Monitoring, Holter Monitoring, PT/INR Testing, along with other Telemedicine Services.
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Company Website and Social Media Outlets:
CB Scientific, Inc. - CBSC website, Twitter, Facebook, Instagram, LinkedIn, and YouTube
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
$CBSC CB Scientific, Inc. Discusses the Potential of Their Proprietary Cardiac Event Monitor, my-Cam, with The Stock Day Podcast https://finance.yahoo.com/news/cb-scientific-inc-discusses-potential-140000069.html
Charles Martin, President and CEO of CB Scientific, Inc. stated, “The acquisition of Cardiolink Corporation fits perfectly into our strategic plan and efforts to positively impact outcomes for the more than 655,000 Americans who die from heart disease in the United States every year. Cardiovascular disease is the leading cause of death in the US, killing one in every four people every year, and costing the US more than $219B annually. The addition of this well-established, proven company, along with our existing and future products and services, will help to solidify CBSC's expanded service offering in our efforts to become a leader in the US Remote Patient Monitoring market. Timely and early detection of potential heart rhythm issues is the key to better diagnosis and improved outcomes, reducing cost and helping to improve quality of life for patients.
$CBSC
Huge news here: ACCESSWIRE / February 23, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring Services market in the United States, is pleased to announce a definitive purchase agreement to acquire Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) based in Levittown, New York. Cardiolink was founded in 1979 and has been providing remote heart arrhythmia monitoring and cardiac support services to the medical community regionally for forty-two years.
This acquisition will provide CBSC with the ability to formally enter the rapidly growing Remote Patient Monitoring (RPM) arena in the US, on a national basis. RPM has become a dominate growth market in the medical field since 2017, primarily due to the increasing occurrence of cardiovascular (heart) disease. Cardiolink, through their 24/7/365 operation, uses state-of-the-art cardiac equipment and software to deliver a wide variety of remote ambulatory cardiac testing services to patients. These wearable devices include Mobile Cardiac Telemetry, Cardiac Event, Extended Holter, Standard Holter and Ambulatory Blood Pressure, all monitored by an experienced staff of well-trained, expert cardiac technicians. Cardiolink also provides remote Pacemaker TTM monitoring and INR heart testing. This acquisition will make CBSC an active player in the domestic Ambulatory Remote Cardiac Diagnostic Monitoring Services market, which generated revenues of approximately US $778M in 2019, with projected future growth of 18% per year.
I'm looking forward to bigger and better things to come from $CBSC as indicated in today's FIRST News Release.
The SECOND $CBSC News from today, February 23, 2021...
CB Scientific, Inc. Discusses the Potential of Their Proprietary Cardiac Event Monitor, my-Cam, with The Stock Day Podcast
https://finance.yahoo.com/news/cb-scientific-inc-discusses-potential-140000069.html
To hear Chip Martin's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7807543-cb-scientific-inc-discusses-the-potential-of-their-proprietary-cardiac-event-monitor-my-cam-w
$CBSC Load and Hold for the big gains $$$
Agreed! As part of CBSC's 2021 business plan, this transaction will help to significantly increase productivity by addressing the ever-increasing demands for remote cardiac services, as well as increasing our revenues, thereby allowing for possible expansion into future alternative markets. Today, the US is at the forefront of Remote Cardiac Monitoring, with lower percentage death rates due to cardiovascular disease, than the rest of the world. Related to this acquisition will be on-going efforts by CBSC to expand My-Cardia's service capabilities globally, where deaths from heart disease in some countries run upwards to 40%. We hope to make a positive impact on these areas of the world by improving earlier diagnosis of heart disease through our products and services. Plans also include leveraging business relationships and exploring additional acquisitions. The Cardiolink acquisition is targeted to be completed by May 2021. $CBSC
I really like companies like CBSC where management goes the extra mile to give investors a clear understanding of the game plan and latest developments. The new podcast out today is an excellent example of this.
From the announcement on the podcast:
Phoenix, Arizona--(Newsfile Corp. - February 23, 2021) - The Stock Day Podcast welcomed CB Scientific, Inc. (OTC Pink: CBSC) ("the Company"), a company transitioning to the Ambulatory Remote Cardiac Monitoring market. CEO of the Company, Chip Martin, joined Stock Day host Everett Jolly.
Martin shared that the Company began transitioning to the Ambulatory Remote Cardiac Monitoring market in June of last year. "This allows us to deal with the early detection of cardiac heart rhythms in hospitals and with cardiologists and physicians around the world and the efforts to diagnose ECG earlier and decrease the amount of deaths related to heart failure," shared Martin.
"What is the new direction for the company?" asked Jolly, after commenting on the Company's proprietary my-Cam cardiac event monitor. "Today, with ambulatory remote cardiac event monitoring, there are actually four modalities that are offered," explained Martin, before elaborating on these technologies. "Our device is cardiac event monitoring, which is a device that can be worn for up to 30 days," said Martin. "Instead of recording everything, this device records a snapshot around when a rhythm problem might occur," he continued. Martin then explained that the snapshot can then be delivered to a physician via the Company's iOS or Android applications to determine whether or not a cardiac problem occurred.
"The device also has a sophisticated algorithm in it that looks at fast, slow, irregular, and delayed heart rates," said Martin. "That particular application has evolved into what's called cardiac event monitoring, which is on the marketplace today, primarily in the US."
"Our primary focus right now has been on Asia, including Thailand, Malaysia, Singapore, and we are also in clinical trials in China for our device today," said Martin. He then explained that these areas typically suffer from lower diagnostic yields due to a lack of availability for cardiac event monitoring devices. "Our device is rather intriguing there," he added. "It is approved for use in Thailand, Malaysia, and Singapore," said Martin, adding that the Company has already launched in Thailand and is hoping to launch in Malaysia and Singapore in the near future.
"How are you getting your story out and what is your marketing plan?" asked Martin. "WHO says that heart disease, cardiovascular disease, takes the lives of 17.9 million people everywhere, which is 31% of the global population," said Martin. "They further state that by 2030 that number will go up to 23.6 million people that will die from heart disease," said Martin. "The cost of heart disease to the US is approximately $219 billion each year," he added. "This isn't going away and there is a real demand for early diagnosis and detection of these arrhythmias," said Martin. "Early detection reduces overall death rates because the heart problems are identified and dealt with proactively. Additionally, early detection is the key to improving the high cost of care and improving the quality of life for patients."
Jolly then asked about the Company's goals moving forward. "The point of least resistance is to get these three distributors up and running in Thailand, Malaysia, and Singapore," said Martin, before noting delays caused by the COVID-19 pandemic. "We're just now getting to where Thailand has product, Malaysia will be getting product next month, and Singapore shortly thereafter," he explained. "We would look for some decent revenues coming out of that area in May or June."
"We have a definitive purchase agreement with a manufacturer here in the US," continued Martin. "That is DATRIX LLC. They are now building our next version of the my-Cam, as well as integrating their product with Sirona into our software," said Martin. "The second piece of that puzzle is for us to complete a definitive purchase agreement with an independent diagnostic testing facility. We're close to getting that done," he continued, adding that this will allow the Company to enter the US market. "It's a growing market. We anticipate that will be in place at the latest by May, as far as having everything in place and owned by us, and then we will be realizing those revenues shortly thereafter."
To close the interview, Martin elaborated on the Company's investment potential as they continue to expand into the Ambulatory Remote Cardiac Monitoring market with their proprietary technology.
To hear Chip Martin's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7807543-cb-scientific-inc-discusses-the-potential-of-their-proprietary-cardiac-event-monitor-my-cam-w
$CBSC More NEWS as CB Scientific, Inc. Discusses the Potential of Their Proprietary Cardiac Event Monitor, my-Cam, with The Stock Day Podcast https://finance.yahoo.com/news/cb-scientific-inc-discusses-potential-140000069.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Big acquisition development for CBSC announced today which should move the company into a very strong position in the vital cardiac monitoring field. This is impressive.
Note the comments from the CEO:
Charles Martin, President and CEO of CB Scientific, Inc. stated, “The acquisition of Cardiolink Corporation fits perfectly into our strategic plan and efforts to positively impact outcomes for the more than 655,000 Americans who die from heart disease in the United States every year. Cardiovascular disease is the leading cause of death in the US, killing one in every four people every year, and costing the US more than $219B annually. The addition of this well-established, proven company, along with our existing and future products and services, will help to solidify CBSC's expanded service offering in our efforts to become a leader in the US Remote Patient Monitoring market. Timely and early detection of potential heart rhythm issues is the key to better diagnosis and improved outcomes, reducing cost and helping to improve quality of life for patients. We look forward to the positive effects that the addition Cardiolink's IDTF operation will have for our company.”
$CBSC News February 23, 2021
CB Scientific, Inc. Discusses the Potential of Their Proprietary Cardiac Event Monitor, my-Cam, with The Stock Day Podcast
https://finance.yahoo.com/news/cb-scientific-inc-discusses-potential-140000069.html
$CBSC News! CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF) https://finance.yahoo.com/news/cb-scientific-inc-announces-definitive-123000184.html
$CBSC CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)
This should be trading $1.50+
This is HUGE $CBSC News!
This acquisition will provide CBSC with the ability to formally enter the rapidly growing Remote Patient Monitoring (RPM) arena in the US, on a national basis. RPM has become a dominate growth market in the medical field since 2017, primarily due to the increasing occurrence of cardiovascular (heart) disease. Cardiolink, through their 24/7/365 operation, uses state-of-the-art cardiac equipment and software to deliver a wide variety of remote ambulatory cardiac testing services to patients.
February 23, 2021
CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)
https://finance.yahoo.com/news/cb-scientific-inc-announces-definitive-123000184.html
$CBSC CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF) https://finance.yahoo.com/news/cb-scientific-inc-announces-definitive-123000184.html?.tsrc=fin-srch
“Cardiolink is very excited to join the CB Scientific, Inc. team in their efforts to address the increasing demand for remote cardiac monitoring services in the U.S.”, said Robert Kammerer, President of Cardiolink Corporation in a statement. Kammerer continued, “With forty-two years of direct experience offering IDTF products and services regionally, Cardiolink looks forward to being a part of CBSC's planned national expansion to further help impact and improve the quality of life and reduce the cost of care for the millions of patients with suspected heart disease, in the U.S.” $CBSC
News: CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)
More content below
Tue, February 23, 2021, 7:30 AM
Addition of IDTF operation has CBSC well-positioned to significantly impact the US Remote Patient Monitoring market.
ESCONDIDO, CA / ACCESSWIRE / February 23, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring Services market in the United States, is pleased to announce a definitive purchase agreement to acquire Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) based in Levittown, New York. Cardiolink was founded in 1979 and has been providing remote heart arrhythmia monitoring and cardiac support services to the medical community regionally for forty-two years.
This acquisition will provide CBSC with the ability to formally enter the rapidly growing Remote Patient Monitoring (RPM) arena in the US, on a national basis. RPM has become a dominate growth market in the medical field since 2017, primarily due to the increasing occurrence of cardiovascular (heart) disease. Cardiolink, through their 24/7/365 operation, uses state-of-the-art cardiac equipment and software to deliver a wide variety of remote ambulatory cardiac testing services to patients. These wearable devices include Mobile Cardiac Telemetry, Cardiac Event, Extended Holter, Standard Holter and Ambulatory Blood Pressure, all monitored by an experienced staff of well-trained, expert cardiac technicians. Cardiolink also provides remote Pacemaker TTM monitoring and INR heart testing. This acquisition will make CBSC an active player in the domestic Ambulatory Remote Cardiac Diagnostic Monitoring Services market, which generated revenues of approximately US $778M in 2019, with projected future growth of 18% per year.
“Cardiolink is very excited to join the CB Scientific, Inc. team in their efforts to address the increasing demand for remote cardiac monitoring services in the U.S.”, said Robert Kammerer, President of Cardiolink Corporation in a statement. Kammerer continued, “With forty-two years of direct experience offering IDTF products and services regionally, Cardiolink looks forward to being a part of CBSC's planned national expansion to further help impact and improve the quality of life and reduce the cost of care for the millions of patients with suspected heart disease, in the U.S.”
Charles Martin, President and CEO of CB Scientific, Inc. stated, “The acquisition of Cardiolink Corporation fits perfectly into our strategic plan and efforts to positively impact outcomes for the more than 655,000 Americans who die from heart disease in the United States every year. Cardiovascular disease is the leading cause of death in the US, killing one in every four people every year, and costing the US more than $219B annually. The addition of this well-established, proven company, along with our existing and future products and services, will help to solidify CBSC's expanded service offering in our efforts to become a leader in the US Remote Patient Monitoring market. Timely and early detection of potential heart rhythm issues is the key to better diagnosis and improved outcomes, reducing cost and helping to improve quality of life for patients. We look forward to the positive effects that the addition Cardiolink's IDTF operation will have for our company.”
As part of CBSC's 2021 business plan, this transaction will help to significantly increase productivity by addressing the ever-increasing demands for remote cardiac services, as well as increasing our revenues, thereby allowing for possible expansion into future alternative markets. Today, the US is at the forefront of Remote Cardiac Monitoring, with lower percentage death rates due to cardiovascular disease, than the rest of the world. Related to this acquisition will be on-going efforts by CBSC to expand My-Cardia's service capabilities globally, where deaths from heart disease in some countries run upwards to 40%. We hope to make a positive impact on these areas of the world by improving earlier diagnosis of heart disease through our products and services. Plans also include leveraging business relationships and exploring additional acquisitions. The Cardiolink acquisition is targeted to be completed by May 2021.
CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
About Cardiolink Corporation:
CardioLink Corp., founded in 1979, has been providing life-saving cardiac support services for physicians and patients, via transtelephonic monitoring equipment for 42 years. The company was incorporated in 1988 and moved from its original facility in Carle Place, NY to a larger facility in Levittown, NY as the company expanded. CardioLink Corp. provides Wireless Telemetry, Cardiac Event Arrhythmia Monitoring, Holter Monitoring, PT/INR Testing, along with other Telemedicine Services.
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Company Website and Social Media Outlets:
CB Scientific, Inc. - CBSC website, Twitter, Facebook, Instagram, LinkedIn, and YouTube
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/631255/CB-Scientific-Inc-Announces-Definitive-Agreement-to-Acquire-Cardiolink-Corporation-an-Independent-Diagnostic-Testing-Facility-IDTF
There is much to be looking forward to with CBSC as described in the new shareholder update. In the near term we should get an announcement on the proposed acquisition of the US based testing facility. This should be a very significant company milestone which can help them meet the growing needs for cardiac monitoring in the healthcare market.
From the CBSC news:
We are in final discussions to secure a Definitive Purchase Agreement to acquire an Independent Device Testing Facility (IDTF) in the US. With this acquisition, we would add the capabilities to immediately provide four necessary testing options, including 24-48hour Holter Monitoring, acoustic and wireless 30-day Cardiac Event monitoring, Mobile Cardiac Telemetry, and 3-21-day Extended Holter Monitoring. Remote patient monitoring is projected to grow 18% in the next five years, according to GlobalData, a leading data, and analytics company.
$CBSC This is starting to get very very exciting!
Vital signs monitoring systems market will expand at a prodigious CAGR of ~5% throughout assessment period 2019–2027. Increased adoption of advanced technologies across healthcare sector will fuel market expansion in years to come $CBSC
Yes, it's one of the most extensive and informative shareholder updates I've ever seen! In addition, $CBSC has a great website with information about their products, management, and even information for investors.
https://cbscientificinc.com/
CBSC management is going a good job of keeping investors informed of the company's progress. The fresh update we just saw issued contains a lot of detail on recent developments and also insight into revenue growth and earnings potential ahead.
CB Scientific Inc. Stock Symbol CBSC issues a Shareholder Update
Current accomplishments and targeted goals have CBSC well-positioned for significant growth in 2021
ESCONDIDO, CA / ACCESSWIRE / February 18, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), is pleased to provide an update on the progress and achievements we have made since transitioning to the Ambulatory Remote Cardiac Monitoring market in June of 2020. While we have faced, like so many others, numerous unforeseen challenges and delays due to the impact of the COVID-19 pandemic, we continue to make significant progress towards our business objectives and strategic goals to help make CBSC a thriving and successful company.
Our targeted market deals directly with the early detection of heart rhythms that can contribute to heart disease. According to the World Health Organization (WHO), cardiovascular disease takes the lives of 17.9 million people every year, or 31% of all global deaths. They further state that by the year 2030, that number will grow to almost 23.6 million people who will die mainly from heart disease and stroke. In the US, the CDC states that 655,000 Americans die from heart disease each year - 1 in every four deaths. Heart disease costs the US alone approximately $219 billion each year. Early and timely detection of heart disease reduces hospital visits and leads to the avoidance of severe future problems. It reduces overall death rates because heart problems are identified and dealt with timely and proactively, reducing the high cost of care and improving the quality of life for the patient.
According to a recent press release from Market Research Engine, dated February 16, 2021, it states that the cardiac monitoring and cardiac rhythm management market is expected to exceed more than US $26 Billion by 2024 at a CAGR of 4% in the given forecast. Their report covers various geographic regions such as North America, Europe, Asia Pacific, Latin American, Middle East, and Africa (https://www.marketresearchengine.com/cardiac-monitoring-and-cardiac-rhythm-management-market). Our my-Cam device is part of this market.
Key accomplishments that CBSC have achieved in the first seven months of operations include:
Launched My-Cardia ECG product services in Thailand (1300+ hospitals -population 66.85 million) through our authorized distributor, Mango Wellness, in October 2020, with expected new accounts in March 2021.
Signed a Definitive Purchase Agreement to acquire US medical device manufacturer DATRIX LLC in October 2020, targeted to close in April 2021. Manufacturing of our proprietary my-Cam cardiac event monitor from China to DATRIX has begun. Testing to incorporate the DATRIX Sirona acoustic and wireless device into our My-Cardia cloud-based portal has started, which will provide additional alternative remote ECG devices to our product offering, both internationally and domestically.
Received device registration and import authorization approval from the Medical Device Authority of Malaysia (384 hospital - population 32M) for the sale and distribution of our my-Cam device into that country, targeted launch in March 2021.
Entered into a Collaborative Partnership Agreement with SHENZHEN SEMACARE MEDICAL TECHNOLOGY COMPANY, LTD. in February 2021. Our two companies will provide mutual assistance pursuing regulatory approvals for our individual products. CBSC will endeavor to consult and assist SEMACARE in their efforts towards regulatory approval of the MetaCor monitoring device for CE and US FDA 510(k) registration. SEMACARE will assist CBSC in the current regulatory approval process with the NMPA in China for the my-Cam monitoring device. During the term of this agreement, mutual efforts will be made towards the joint development of products, including interoperability between SEMACARE monitoring products and CB Scientific's current and future monitoring solutions. This includes assistance by SEMACARE to help develop a wireless, waterproof patch solution for CBSC devices.
Continuing ongoing clinical trials of our my-Cam device, associated cloud-based software portal, smartphone apps, and WeChat app continue in our pursuit of NMPA (formally CFDA) device certification approval in China. Through January 2021, CBSC is in trials with our device in 40 hospitals, with more than 250,000 successful transmissions on the WeChat app. To date, we maintain a 99%+ success rating. Along with assistance from SEMACARE, we hope to move closer to the approval of the device soon.
Completing my-Cam device and software portal set-up to include regulatory and registration approval for the country of Singapore (population 5.8M), with a targeted distribution launch there in April 2021.
We are in final discussions to secure a Definitive Purchase Agreement to acquire an Independent Device Testing Facility (IDTF) in the US. With this acquisition, we would add the capabilities to immediately provide four necessary testing options, including 24-48hour Holter Monitoring, acoustic and wireless 30-day Cardiac Event monitoring, Mobile Cardiac Telemetry, and 3-21-day Extended Holter Monitoring. Remote patient monitoring is projected to grow 18% in the next five years, according to GlobalData, a leading data, and analytics company.
With the upcoming launch of our distributors in the Asia Pacific region, the completion of our targeted acquisitions in the US, and the exploration of other geographic market expansions, CBSC is poised for significant growth in 2021 and beyond.
CB Scientific plans to make further announcements to keep its shareholders, industry participants, and the public markets informed through press releases and regulatory filings as new developments occur.
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
$CBSC Increase in Instances of Critical Health Issues Fuels Vital Signs Monitoring Systems Market: TMR https://markets.businessinsider.com/news/stocks/increase-in-instances-of-critical-health-issues-fuels-vital-signs-monitoring-systems-market-tmr-1030087839
CB Scientific is a publicly traded (OTC: $CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space.
The Cloud-Based Web Portal My-Cardia provides a 24 x 7 monitoring service featuring innovative devices and software to simplify 30 day event monitoring for both patients and Physicians...
My Cardia uses a small footprint discrete Auto Trigger ECG recording device worn by the patient for up to 30 days. The monitor can record both patient activated ECGs as well as asymptomatic. events detected by the on board analysis algorithm. The my CAM device is single use – each patient receives a brand new monitor and there is no need for the patient to return the device at the end of the recording period. Recorded ECGs are easy to transmit using either a land line or a mobile phone. ECG reports can be reviewed and/or printed using our cloud-based software which can be accessed from computers, tablets and mobile phones.
Features
30 Day auto-trigger AF and rate detection
Single user only, non-reusable device
Acoustic transmission via mobile or landline
Smart lead on/off status indication
24/7 cloud based service, analysis and reports
$CBSC current accomplishments and targeted goals have #CBSC well-positioned for significant growth in 2021
#CBScientificInc #ShareholderUpdate
$CBSC current accomplishments and targeted goals have #CBSC well-positioned for significant growth in 2021 #CBScientificInc #ShareholderUpdatehttps://t.co/Uk9TZPn2NR
— CB Scientific, Inc. (@cbscientificinc) February 18, 2021
$CBSC issues a Shareholder Update https://yhoo.it/3bqBymh
My-Cardia (USA) Inc. is a wholly owned subsidiary of CB Scientific and provides ambulatory Cardiac Event Monitoring services in the US as well as provides the device, software, smartphone app, IT support, technical and clinical support for all international distributor operations and Chinese locations under our umbrella.
CB Scientific Inc. is Currently trading on OTC Markets under the ticker symbol $CBSC. https://cbscientificinc.com/investors/
Looking forward to next week's trading session.
$CBSC
A truly innovative product with many amazing features...$CBSC
Yes, the CBSC website covers the value points of the company for investors and clearly explains the company's products such as the very successful "my Cam" system.
From the site:
Our innovative my Cam ambulatory ECG recorder is extremely small and convenient for patients to wear and use. The monitor has a single button for recording and transmitting ECG events and does not require batteries to be changed during the recording period. In addition to patient activation to record ECGs the device features an auto-trigger algorithm that can automatically record the ECG if it detects atrial fibrillation, tachycardia, bradycardia and pauses. The algorithm can also detect if a lead has fallen off which greatly reduces false positive ECG recordings. The patient can transmit recorded ECGs using both land line and smart phones.
Features
Patient-activated Loop event recorder
Auto-trigger for capturing asymptomatic events (Tachycardia, Bradycardia, Atrial Fibrillation, Pause)
Smart Lead on/off status indication reduces false positive recordings
Acoustic ECG transmission via land line or mobile phone with iOs and Android compatibility
Single-use device – no need to return the device after monitoring period
24/7 monitoring service with cloud-based access to reports from any device
That's some great information about $CBSC!
If you click on the link below, you will learn more about the company's mission statement, what they offer, and their leadership team.
http://cbscientificinc.com/company/
Why you should be watching CB Scientific, Inc. - CBSC .: #CBSC
CB Scientific, Inc. OTC: CBSC is poised for a possible breakout year! CB Scientific develops and sells Auto Trigger ECG recording devices, called myCam, a low-cost disposable cardiac monitor which provides the physician with a discrete medical device recording technology that improves patient compliance, lowers cost, and is simple to use reducing patient risk by helping physicians to identify cardiac rhythm issues.
CB Scientific Inc. Stock Symbol CBSC issues a Shareholder Update Join the conversation
CBSC is poised for significant growth in 2021 and beyond.
CB Scientific plans to make further announcements to keep its shareholders, industry participants, and the public markets informed through press releases and regulatory filings as new developments occur.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
579
|
Created
|
01/18/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |